MedTrace Logo

Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk

NCT05098704 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-07-14

No results posted yet for this study

Summary

Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific anti-nuclear antibodies is the hallmark of pre-scleroderma subjects, among who around 47% declare a complete disease after five years. The aim of this study is to assess in this particular population the preventive effect of an anti-platelet treatment.

Conditions

Interventions

DRUG

clopidogrel treatment

75 mg daily during 24 months

DRUG

Placebo

75 mg daily during 24 months

Sponsors & Collaborators

  • Ministry for Health and Solidarity, France

    collaborator OTHER_GOV

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Marie-Elise TRUCHETET, Prof · University Hospital, Bordeaux

  • Linda WITTKOP, MD · University of Bordeaux

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2031-06-30
Completion
2031-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05098704 on ClinicalTrials.gov